SIBN
What one share of Si-Bone holds
Surgical and Medical Instruments and Apparatus
We are a leader in developing innovative procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific innovation. As pioneers of minimally invasive treatment for sacroiliac joint dysfunction and degeneration, we have developed a deep competency in addressing the challenges of low-density bone in the sacrum.
Si-Bone’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.88 |
|---|---|
| Profit | −$0.33 |
| Capex (buildings and equipment) | $0.16 |
| Free cash flow | −$0.10 |
| Cash and investments | $0.74 |
| Debt | $0.80 |
| Book value | $4.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $13.84 | −$6.64 | $0.14 | −$5.19 | $0.00 | −$35.91 |
| 2018 | $6.97 | −$2.20 | $0.12 | −$1.94 | $0.00 | — |
| 2019 | $2.72 | −$1.55 | $0.10 | −$1.38 | $0.00 | $2.50 |
| 2020 | $2.53 | −$1.50 | $0.09 | −$1.14 | $0.00 | $5.20 |
| 2021 | $2.72 | −$1.71 | $0.19 | −$1.39 | $0.00 | $3.99 |
| 2022 | $3.11 | −$1.79 | $0.28 | −$1.50 | $0.00 | $2.83 |
| 2023 | $3.61 | −$1.13 | $0.20 | −$0.69 | $0.00 | $4.16 |
| 2024 | $4.03 | −$0.75 | $0.25 | −$0.55 | $0.00 | $3.97 |
| 2025 | $4.68 | −$0.44 | $0.20 | −$0.21 | $0.00 | $4.07 |